Apollon Formularies (AQSE:APOL) Cash And Cash Equivalents : £0.05 Mil (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Cash And Cash Equivalents?

Apollon Formularies's quarterly cash and cash equivalents declined from Dec. 2021 (£0.31 Mil) to Jun. 2022 (£0.00 Mil) but then increased from Jun. 2022 (£0.00 Mil) to Jun. 2023 (£0.05 Mil).

Apollon Formularies's annual cash and cash equivalents declined from Dec. 2019 (£0.10 Mil) to Dec. 2020 (£0.00 Mil) but then increased from Dec. 2020 (£0.00 Mil) to Dec. 2021 (£0.31 Mil).

Apollon Formularies Cash And Cash Equivalents Historical Data

The historical data trend for Apollon Formularies's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Cash And Cash Equivalents Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.44

0.10

0.31

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Cash And Cash Equivalents	Get a 7-Day Free Trial											-	1.26	0.31	-	0.05

Apollon Formularies Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Apollon Formularies (AQSE:APOL) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Apollon Formularies Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.